97776-05-1

Usage

InChI:InChI=1/C8H5BrF3NO2/c9-5-2-3(7(14)15)1-4(6(5)13)8(10,11)12/h1-2H,13H2,(H,14,15)

Upstream product

• 88-17-5 2-(trifluoromethyl)benzenamine 
• 175277-96-0 N-(4-cyano-2-(trifluoromethyl)phenyl)acetamide 
• 97760-98-0 N-(4-iodo-2-(trifluoromethyl)phenyl)acetamide 
• 97760-97-9 4-iodo-2-(trifluoromethyl)aniline 
• 400-76-0 4-amino-3-(trifluoromethyl)benzoic acid 

Downstream Products

• 97804-09-6 diethyl 2-(4-amino-3-bromo-5-trifluoromethyl-benzoyl)-malonate 
• 688020-70-4 (4-amino-3-bromo-5-trifluoromethyl-phenyl)-methanol 
• 63498-20-4 4-amino-3-bromo-5-trifluoromethyl-benzoyl chloride 

Relevant academic research and scientific papers

SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT

The invention relates to CGRP antagonists of general formula (I), in which A, U, V, W, X and R1 to R 3 are as defined in claim 1, the tautomers, diastereomers, enantiomers, hydrates, mixtures, salts, hydrates of the salts, in particular the physiologically-acceptable salts thereof with inorganic or organic acids, medicaments containing said compounds and the use and methods for production thereof.

Synthesis of further amino-halogen-substituted phenyl-aminoethanols

Starting from clenbuterol as a lead structure, new 4-amino-phenyl-aminoethanol analogues have been synthesized by different approaches. In these compounds one or both of the chlorine atoms of clenbuterol are replaced by other residues. This has led to compounds with high intrinsic β2-mimetic and/or β1-blocking activities. 1-(4-Amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert.-butylamino-ethanol hydrochloride (mabuterol) has been selected for clinical development. A detailed description is also given of the syntheses of new intermediate acetophenone derivatives as well as of the resolution of mabuterol into its enantiomers.